264 related articles for article (PubMed ID: 36811662)
21. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Tan Z; Zhang J; Xu L; Wang H; Mao X; Zou R; Wang Q; Han Z; Di Z; Wu D
PLoS One; 2023; 18(10):e0290644. PubMed ID: 37844117
[TBL] [Abstract][Full Text] [Related]
22. Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors - a systematic review and meta-analysis.
Dawood ZS; Brown ZJ; Alaimo L; Lima HA; Shaikh C; Katayama ES; Munir MM; Moazzam Z; Endo Y; Woldesenbet S; Pawlik TM
HPB (Oxford); 2024 May; 26(5):618-629. PubMed ID: 38369433
[TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
Ng KYY; Wong LWJ; Ang AJS; Lee AWX; Tay DSH; Tan JJE; Tan SH; Choo SP; Tai DW; Lee JJX
Asia Pac J Clin Oncol; 2023 Jun; 19(3):312-319. PubMed ID: 35950298
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
[TBL] [Abstract][Full Text] [Related]
25. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice.
Pinato DJ; Marron TU; Mishra-Kalyani PS; Gong Y; Wei G; Szafron D; Sharon E; Saeed A; Jun T; Dharmapuri S; Naqash AR; Peeraphatdit T; Gampa A; Wang Y; Khan U; Muzaffar M; Navaid M; Lee CJ; Lee PC; Bulumulle A; Yu B; Paul S; Nimkar N; Bettinger D; Hildebrand H; Abugabal YI; Pressiani T; Personeni N; D'Alessio A; Kaseb AO; Huang YH; Ang C; Schneider J; Pillai A; Rimassa L; Goldberg KB; Pazdur R; Theoret M; Lemery S; Fashoyin-Aje '; Cortellini A; Pelosof L
Eur J Cancer; 2021 Nov; 157():140-152. PubMed ID: 34508996
[TBL] [Abstract][Full Text] [Related]
26. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
27. The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
Peng W; Pan Y; Xie L; Yang Z; Ye Z; Chen J; Wang J; Hu D; Xu L; Zhou Z; Chen M; Fang A; Zhang Y
Therap Adv Gastroenterol; 2024; 17():17562848241237631. PubMed ID: 38645513
[TBL] [Abstract][Full Text] [Related]
28. Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis.
Tian BW; Yan LJ; Ding ZN; Liu H; Han CL; Meng GX; Xue JS; Dong ZR; Yan YC; Hong JG; Chen ZQ; Wang DX; Li T
Int Immunopharmacol; 2023 Jan; 114():109519. PubMed ID: 36459922
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status.
Lee SW; Lee TY; Peng YC; Yang SS; Yeh HZ; Chang CS
Medicine (Baltimore); 2019 Nov; 98(44):e17692. PubMed ID: 31689794
[TBL] [Abstract][Full Text] [Related]
30. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis.
Finn RS; Zhu AX; Farah W; Almasri J; Zaiem F; Prokop LJ; Murad MH; Mohammed K
Hepatology; 2018 Jan; 67(1):422-435. PubMed ID: 28881497
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
[TBL] [Abstract][Full Text] [Related]
32. The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors.
Zhang L; Chen C; Chai D; Li C; Guan Y; Liu L; Kuang T; Deng W; Wang W
Front Immunol; 2022; 13():956533. PubMed ID: 36059512
[TBL] [Abstract][Full Text] [Related]
33. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
Xie F; Chen B; Yang X; Wang H; Zhang G; Wang Y; Wang Y; Zhang N; Xue J; Long J; Li Y; Sun H; Xun Z; Liu K; Chen X; Song Y; Yang X; Lu Z; Mao Y; Sang X; Lu Y; Zhao H
Front Immunol; 2022; 13():1052937. PubMed ID: 36569829
[TBL] [Abstract][Full Text] [Related]
35. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
36. Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis.
Deng R; Zhang H; Li Y; Shi Y
J Immunother; 2023 Feb-Mar 01; 46(2):43-55. PubMed ID: 36301729
[TBL] [Abstract][Full Text] [Related]
37. The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study.
Wada Y; Takami Y; Matsushima H; Tateishi M; Ryu T; Yoshitomi M; Matsumura T; Saitsu H
Intern Med; 2018 May; 57(10):1345-1353. PubMed ID: 29279513
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials.
Huang D; Ke L; Cui H; Li S
BMC Cancer; 2023 May; 23(1):474. PubMed ID: 37226111
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
[TBL] [Abstract][Full Text] [Related]
40. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]